PharmAust Ltd. announced it has executed a Data and Regulatory Rights Agreement with Elanco US Inc. to assist in the development of monepantel as an anticancer therapeutic in dogs. Under this agreement, Elanco will permit PharmAust to reference certain Elanco controlled safety and blood chemistry data that were generated for the regulatory approval of monepantel in Australia, New Zealand and 27 countries within the European Union, as an anti-parasitic drug in livestock animals. This Data and Regulatory Rights Agreement supports the Option Agreement executed between Elanco and PharmAust on 12 April 2018, providing PharmAust with the ability to more efficiently develop its Phase II clinical trials in dogs.